Evidence map›Paper›PMID 25569667›Full record

ArticleMedicine2015

Cyclosporine for the treatment of HLTV-1-induced HAM/TSP: an experience from a case report.

Adrián Sánchez-Montalvá, Fernando Salvador, Estrella Caballero, Israel Molina

Erratum issuedOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Efgartigimod Combined With Steroid Treatment for HAM/TSP: A Case Report.Annals of clinical and translational neurology · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Adrián Sánchez-MontalváFrom the Infectious Diseases Department (AS-M, FS, IM), PROSICS (International Health Program of the Catalan Health Institute), Vall d'Hebron University Hospital, Universitat Autonòma de Barcelona, Barcelona, Spain; and Microbiology Department (EC), Vall d'Hebron Universitary Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Fernando Salvador
Estrella Caballero
Israel Molina
Universitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) remains a challenging disease. Treatment options are scarce, and their safety and efficacy are currently a matter of concern.We present a case report describing our experience using cyclosporine in a patient with early HAM/TSP who started with a gait disturbance at Vall d'Hebron University Hospital (Barcelona) from August 2012 to October 2013. After 62 weeks of treatment, clinical improvement was observed and proviral load diminished. No safety concerns were observed.Cyclosporine seems to be effective in new-onset HAM/TSP or in chronic HAM/TSP that develops a relapse. However, the duration and safety profile of this steroid-sparing therapy remain unknown and should be further investigated.

Indexed as

AdultCyclosporineFemaleHumansImmunosuppressive AgentsParaparesis, Tropical SpasticCyclosporineImmunosuppressive Agents

Identifiers

PMID25569667
PMCPMC4602838
OpenAlexW2333522691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.